Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.

Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.

Hum Vaccin. 2007 Sep-Oct;3(5):205-11. Epub 2007 May 18.

PMID:
17881903
2.

Listeriolysin O secreted by Listeria monocytogenes into the host cell cytosol is degraded by the N-end rule pathway.

Schnupf P, Zhou J, Varshavsky A, Portnoy DA.

Infect Immun. 2007 Nov;75(11):5135-47. Epub 2007 Aug 6.

3.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9. Epub 2006 Jun 5.

PMID:
16797805
4.

Plasmid-encoded regulator of extracellular proteases in Bacillus anthracis.

Aronson AI, Bell C, Fulroth B.

J Bacteriol. 2005 May;187(9):3133-8.

5.

Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.

Zhang S, Finkelstein A, Collier RJ.

Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16756-61. Epub 2004 Nov 17.

6.

Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Quinn CP, Dull PM, Semenova V, Li H, Crotty S, Taylor TH, Steward-Clark E, Stamey KL, Schmidt DS, Stinson KW, Freeman AE, Elie CM, Martin SK, Greene C, Aubert RD, Glidewell J, Perkins BA, Ahmed R, Stephens DS.

J Infect Dis. 2004 Oct 1;190(7):1228-36. Epub 2004 Aug 30.

7.

Validation of the anthrax lethal toxin neutralization assay.

Hering D, Thompson W, Hewetson J, Little S, Norris S, Pace-Templeton J.

Biologicals. 2004 Mar;32(1):17-27.

PMID:
15026022
8.

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP.

Vaccine. 2004 Jan 2;22(3-4):422-30.

PMID:
14670324
9.

In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM.

Vaccine. 2001 Sep 14;19(32):4768-73.

PMID:
11535328
10.

Optimized production and purification of Bacillus anthracis lethal factor.

Park S, Leppla SH.

Protein Expr Purif. 2000 Apr;18(3):293-302.

PMID:
10733882
11.

Role of toxin functional domains in anthrax pathogenesis.

Brossier F, Weber-Levy M, Mock M, Sirard JC.

Infect Immun. 2000 Apr;68(4):1781-6.

12.

Characterization of membrane translocation by anthrax protective antigen.

Wesche J, Elliott JL, Falnes PO, Olsnes S, Collier RJ.

Biochemistry. 1998 Nov 10;37(45):15737-46.

PMID:
9843379
13.

Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages.

Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C.

Biochem Biophys Res Commun. 1998 Jul 30;248(3):706-11.

PMID:
9703991
14.

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF.

Science. 1998 May 1;280(5364):734-7.

15.

Expression and purification of the recombinant lethal factor of Bacillus anthracis.

Gupta P, Batra S, Chopra AP, Singh Y, Bhatnagar R.

Infect Immun. 1998 Feb;66(2):862-5.

16.

The N-end rule: functions, mysteries, uses.

Varshavsky A.

Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12142-9. Review.

17.

In vivo half-life of a protein is a function of its amino-terminal residue.

Bachmair A, Finley D, Varshavsky A.

Science. 1986 Oct 10;234(4773):179-86.

PMID:
3018930
Items per page

Supplemental Content

Write to the Help Desk